Astria Therapeutics Inc (ATXS) FinancialsATXSAstria Therapeutics Inc

Evaluating the bottom line, Astria Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4830.59%, while the net margin is -4482.01%. These profitability ratios, combined with a Return on Equity (ROE) of -64.56%, provide a clear picture of how effectively ATXS converts its operational activities into shareholder value.

In the context of the broader market, ATXS competes directly with industry leaders such as GYRE and FULC. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, ATXS's gross margin of 100.00% stands against GYRE's 92.41% and FULC's N/A. Such benchmarking helps identify whether Astria Therapeutics Inc is trading at a premium or discount relative to its financial performance.

In Q3 2025, revenue remained flat at $706,000 YoY. Net income improved by 28.98% YoY but remains negative at -31.64M. EPS improved by 30.95% YoY to -0.55. Gross margin stayed at 100%. Overall, the company is still unprofitable.